The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
Open accessAbstract
Background ZyCoV-D, a DNA-based vaccine, showed promising safety and immunogenicity in a phase 1/2 trial. We now report the interim efficacy results of phase 3 clinical trial with ZyCoV-D vaccine in India. Methods We conducted an interim analysis of a multicentre, double-blind, randomised, placebo-controlled phase 3 trial at 49 centres in India. Healthy participants aged at least 12 years were enrolled and randomly assigned (1:1) to receive either ZyCov-D vaccine (Cadila Healthcare; 2 mg per dose) or placebo. An interactive web response system was used for randomisation (blocks of four) of participants as well as to enrol those aged 60 years and older with or without comorbid conditions, and those aged 12–17 years. It was also used to identify 600 participants for immunogenicity (blocks of six). Participants, investigators, and outcome assessors were masked to treatment assignment. Three doses of vaccine or placebo were administered intradermally via a needle-free injection system 28 days apart. The primary outcome was the number of participants with first occurrence of symptomatic RT-PCR-positive COVID-19 28 days after the third dose, until the targeted number of cases (interim analysis n=79, full analysis n=158) have been achieved. The analysis was done in the per-protocol population, which consisted of all participants with negative baseline SARS-CoV-2 status who received three doses of vaccine or placebo. Assessment of safety and tolerability was based on the safety population, which consisted of all enrolled participants who were known to have received at least one dose of study vaccine or placebo. This trial is registered with Clinical Trial Registry India, CTRI/2021/01/030416, and is ongoing. Findings Between Jan 16, and June 23, 2021 (data cutoff), 33 194 individuals were screened, of whom 5241 did not meet screening criteria and 27 703 were enrolled and randomly assigned to receive ZyCoV-D (n=13 851) or placebo (n=13 852). Per-protocol, 81 cases were eligible and included in efficacy analysis (20 of 12 350 in the ZyCoV-D group and 61 of 12 320 in placebo group). The ZyCoV-D vaccine efficacy was found to be 66·6% (95% CI 47·6–80·7). The occurrence of solicited adverse events was similar between the treatment groups (623 [4·49%] in the ZyCoV-D group vs 620 [4·47%] in the placebo group). There were two deaths (one in each group) reported at the data cutoff, neither of which was considered related to the study treatments. Interpretation In this interim analysis, ZyCoV-D vaccine was found to be efficacious, safe, and immunogenic in a phase 3 trial. Funding National Biopharma Mission, Department of Biotechnology, Government of India and Cadila Healthcare, Ahmedabad, Gujarat India.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00306-8 · Cited by 1,288
Clinical course and mortality risk of severe COVID-19
Weiss, P., & Murdoch, D. R. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30633-4 · Cited by 688
Momin, T., Kansagra, K., Patel, H., Sharma, S., Sharma, B., Patel, J., Mittal, R., Sanmukhani, J., Maithal, K., Dey, A., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101020 · Cited by 185
Self-citationImmunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
Dey, A., Rajanathan, T. M. C., Chandra, H., Pericherla, H. P. R., Mendiratta, S. K., Choonia, H. S., Bajpai, M., Singh, A. K., Sinha, A., Saini, G., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.098 · Cited by 147
Self-citationLessons from SARS-CoV-2 in India: A data-driven framework for pandemic resilience
Salvatore, M., Bhattacharyya, R., Purkayastha, S., Zimmermann, L., Ray, D., Hazra, A., Kleinsasser, M., Mellan, T. A., Whittaker, C., Flaxman, S. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8621 · Cited by 71
Mammen, M. P., Tebas, P., Agnes, J. T., Giffear, M., Kraynyak, K. A., Blackwood, E., Amante, D. H., Reuschel, E. L., Purwar, M., Christensen-Quick, A., et al. (2021) · medRxiv · doi:10.1101/2021.05.07.21256652 · Cited by 44
Cited by
Yang, Z.-R., Jiang, Y.-W., Li, F.-X., Liu, D., Lin, T.-F., Zhao, Z.-Y., Wei, C., Jin, Q.-Y., Li, X.-M., Jia, Y.-X., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00390-1 · Cited by 138
Metadata
- Authors
- Khobragade, A., Bhate, S., Ramaiah, V., Deshpande, S., Giri, K., Phophle, H., Supe, P., Godara, I., Revanna, R., Nagarkar, R., Sanmukhani, J., Dey, A., Rajanathan, T. M. C., Kansagra, K., & Koradia, P.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 399
- Issue
- 10332
- Pages
- 1313-1321
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4220680697
- Cited by
- 253
- References
- 7
- FWCI
- 26.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00151-9
- The paper
- Khobragade, A., Bhate, S., Ramaiah, V., Deshpande, S., Giri, K., Phophle, H., Supe, P., Godara, I., Revanna, R., Nagarkar, R., Sanmukhani, J., Dey, A., Rajanathan, T. M. C., Kansagra, K., & Koradia, P. (2022). Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. The Lancet. https://doi.org/10.1016/s0140-6736(22)00151-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.